Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688336's EV-to-FCF is ranked worse than 50.3% of 338
companies
in the Biotechnology industry
Industry Median: 15.02
vs SHSE:688336: 15.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sunshine Guojian Pharmaceutical (Shanghai) Co's PE Ratio (TTM) for today is calculated as:
Sunshine Guojian Pharmaceutical (Shanghai) Co's share price for today is ¥44.40.
Sunshine Guojian Pharmaceutical (Shanghai) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.311.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sunshine Guojian Pharmaceutical (Shanghai) Co EV-to-FCF Related Terms
Sunshine Guojian Pharmaceutical (Shanghai) Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co EV-to-FCF Chart
Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Guojian Pharmaceutical (Shanghai) Co EV-to-FCF vs Biotechnology Industry
Sunshine Guojian Pharmaceutical (Shanghai) Co's current Enterprise Value is ¥38,198 Mil.
Sunshine Guojian Pharmaceutical (Shanghai) Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,527 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a EV-to-FCF of 15.11 as of Jul. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. This is 14% above median its historical median of 13.23. According to the industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #170 out of 338 companies in the Biotechnology industry, placing it in the top 50.3%.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's EV-to-FCF too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current EV-to-FCF of 15.11 is 14% above median its 10-year median of 13.23. The Biotechnology industry median EV-to-FCF is 15.02. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 15.11 is 0.6% above this industry median. Based on the distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #170 out of 338 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 81/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #170 out of 338 companies for EV-to-FCF. This places Sunshine Guojian Pharmaceutical (Shanghai) Co in the lower half of its industry. The industry median EV-to-FCF is 15.02. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 15.11 is 0.6% above this benchmark. While the company's 10-year median is 13.23 vs. the industry median of 15.02, Sunshine Guojian Pharmaceutical (Shanghai) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.02, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Guojian Pharmaceutical (Shanghai) Co's current EV-to-FCF of 15.11 is 0.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Guojian Pharmaceutical (Shanghai) Co's current EV-to-FCF is 15.11, which is 14% above median its own 10-year median of 13.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Possible Value Trap. The stock's GF Value™ is ¥67.28, compared to a current price of ¥44.40 — trading 34% below its estimated fair value. The current EV-to-FCF is 15.11, which is 14% above median its 10-year median of 13.23 and 0.6% above the Biotechnology industry median of 15.02. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current EV-to-FCF is 15.11 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued.
The current stock price of ¥44.40 is trading 34% below its estimated GF Value™ of ¥67.28.
GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Possible Value Trap.
Key valuation signals for SHSE:688336:
EV-to-FCF: 15.11 (14% above median its 10-year median of 13.23)
GF Value™: ¥67.28 vs. price of ¥44.40 (34% below fair value)
Industry Position: 0.6% above the Biotechnology median (#170 of 338)
No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
81GF Score
Get the complete analysis for SHSE:688336
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688336 has been successfully added to your 
